The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kalyn Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Emelin A.Iu.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Kashin A.V.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gustov A.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Antipenko E.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Korshunova Iu.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Davydova T.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Messler G.

Ébeve Neĭro Farma GmbKh, Avstriia

Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment

Authors:

Gavrilova S.I., Kolykhalov I.V., Fedorova Ia.B., Selezneva N.D., Kalyn Ia.B., Roshchina I.F., Odinak M.M., Emelin A.Iu., Kashin A.V., Gustov A.V., Antipenko E.A., Korshunova Iu.A., Davydova T.A., Messler G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(1): 62‑69

Read: 1960 times

Download PDF (RU)
Contact the author
Table of contents

POSSIBILITIES OF PREVENTIVE TREATMENT OF ALZHEIMER'S DISEASE: RESULTS OF THE 3-YEAR OPEN PROSPECTIVE COMPARATIVE STUDY ON EFFICACY AND SAFETY OF THE COURSE THERAPY WITH CEREBROLYSIN AND CAVINTON IN ELDERLY PATIENTS WITH THE SYNDROME OF MILD COGNITIVE IMPAIRMENT
POSSIBILITIES OF PREVENTIVE TREATMENT OF ALZHEIMER'S DISEASE: RESULTS OF THE 3-YEAR OPEN PROSPECTIVE COMPARATIVE STUDY ON EFFICACY AND SAFETY OF THE COURSE THERAPY WITH CEREBROLYSIN AND CAVINTON IN ELDERLY PATIENTS WITH THE SYNDROME OF MILD COGNITIVE IMPAIRMENT

To cite this article:

Gavrilova SI, Kolykhalov IV, Fedorova IaB, et al. . Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(1):62‑69. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Cere­brolysin and the opti­mal timing of anti­coagulation resu­mption in stroke: combined post hoc survival analysis of the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):77-93
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Change of subjective cognitive decline in first-degree rela­tives of patients with Alzheimer’s disease: resu­lts of a 15-year prospective study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):36-42
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Abstract:

The study was conducted in 3 Russian centers (Moscow, St. Petersburg and Nizhniy Novgorod). The total sample included 110 patients whose mental state met the definition of «mild cognitive impairment» (MCI). Patient's status was assessed with widely used scales (MMSE, GDS, CDR etc) and a battery of neuropsychological tests. Genotyping for the APOE polymorphism was performed as well. Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton. The superiority of cerebrolysin over cavinton in slowing down of the cognitive deficit progression and delaying the time or transition of patients to the diagnostic category of Alzheimer's disease was demonstrated. Cerebrolysin was particularly effective in MCI patients with the ApoE(+) genotype, i.e. in those with higher risk for Alzheimer's disease. Adverse effects during the treatment were rare in both groups.

Keywords:

mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
mild cognitive impairment
cavinton
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
mild cognitive impairment
cavinton
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
mild cognitive impairment
cavinton
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
mild cognitive impairment
cavinton
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton
mild cognitive impairment
Alzheimer's disease
preventive treatment
cerebrolysin
cavinton

Authors:

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kalyn Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Emelin A.Iu.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Kashin A.V.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gustov A.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Antipenko E.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Korshunova Iu.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Davydova T.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Messler G.

Ébeve Neĭro Farma GmbKh, Avstriia

Close metadata

References:

  1. Belousov Yu.B., Mednikov O.N., Chikina E.S. Farmakoekonomicheskie aspekty lecheniya dementsii v RF. Rus med zhurn 2005;13:20:1354.
  2. Gavrilova S.I., Kolykhalov I.V., Selezneva N.D. i dr. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie vliyaniya tserebrolizina na effektivnost' i perenosimost' posleduyushchei kholinergicheskoi terapii u bol'nykh s bolezn'yu Al'tsgeimera. Sots i klin psikhiat 2000;2:41-46.
  3. Gavrilova S.I., Kalyn Ya.B. Suitsidal'no-sredovye faktory i sostoyanie psikhicheskogo zdorov'ya pozhilogo naseleniya. Vestn RAMN 2002;9:15-20.
  4. Gavrilova S.I. Neirotroficheskaya i neiroprotektivnaya terapiya. V kn.: Farmakoterapiya bolezni Al'tsgeimera. M: Pul's 2003;185-224.
  5. Gavrilova S.I., Kolykhalov I.V., Korovaitseva G.I. i dr. AroE genotip i effektivnost' neirotroficheskoi i kholinergicheskoi terapii pri bolezni Al'tsgeimera. Zhurn nevrol i psikhiat 2005;105:4:27-33.
  6. Gavrilova S.I., Fedorova Ya.B., Kolykhalov I.V. i dr. Terapevticheskii potentsial tserebrolizina v preventivnoi terapii bolezni Al'tsgeimera. Zhurn nevrol i psikhiat 2008;108:8:24-28.
  7. Gavrilova S.I. Vozmozhnosti doklinicheskoi diagnostiki i preventivnogo terapevticheskogo vmeshatel'stva pri bolezni Al'tsgeimera. V kn.: Bolezn' Al'tsgeimera i kognitivnye narusheniya v pozhilom vozraste: dostizheniya v neirobiologii i terapii. M: Pul's 2008;6-32.
  8. Gerasimov N.P. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie effektivnosti tserebrolizina pri bolezni Al'tsgeimera. Sots i klin psikhiat 2000;2:35-40.
  9. Kalyn Ya.B., Gavrilova S.I. Epidemiologicheskie i farmako-ekonomicheskie aspekty bolezni Al'tsgeimera. V kn.: Bolezn' Al'tsgeimera i kognitivnye narusheniya v pozhilom vozraste: dostizheniya v neirobiologii i terapii. M: Pul's 2008;275-285.
  10. Alvares X.A., de Olano M., Sampedro C. et al. Cerebrolysin protect against neurodegeneration induced by β-amyloid implants in rats. Int J Neuropsychopharmac 2000;3:359.
  11. Alvarez X.A., Lombardi V.R., Fernandez–Novoa L. et al. Cerebrolysin reduces microglial activation in-vivo and in-vitro: a potencial mechanism of neuroprotection. J Neurol Transm 2000;59:Suppl:281-292.
  12. Alvares X.A., Cacabelos R., Laredo M. et al. A 24-week, double-blind, placebo-controlled study of dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006;13:43-54.
  13. Chen Y., Tung Yu., Li B. et al. Trophic factor counteract elevated FGF-2 unduced inhibition of adult neurogenesis . Neurobiol Aging 2007;28:1148-1162.
  14. Golomb J., Kluger A., Garrard P., Ferris S. Clinician's Manuel on Mild Cognitive Impairment. Science. London: Press Ltd 2001;56.
  15. Gschanes A., Windish M. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neurol Trasmis 1998;53:Suppl:
  16. Low L.F., Anstey K.J. Dementia literacy: Recognition and Reliegs on Dementia of the Australian public. J Alzheimer's Dementia 2009;5:43-49.
  17. Masliah E., Armasolo F., Veinberg I. et al. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behavior 1999;62:239-245.
  18. Maslow K. How many people with dementia are hospitalized? In: Improving hospital care for persons with dementia. Eds. N.M. Silvertein, K. Maslow. New York: Springer 2006;3-21.
  19. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
  20. Petersen R.C., Smith G.E., Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
  21. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004;256:183-194.
  22. Reinprecht I., Gschanes A., Windish M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochemical J 1999;31:395-401.
  23. Reisberg B., Ferris S.H., de Leon M.J. et al. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982;139:1136-1139.
  24. Ruther E., Ritter R., Apecechea M. et al. Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with senile dementia of the Alzheimer Type. Pharmacopsychiatry 1994;27:1:32-40.
  25. Sallaw A., Mintzez J., Weiner M., Cummings J. Disease-modifying therapies in Alzheimer's disease. J Alzheimer's Dementia 2008;4:65-79.
  26. Windisch M., Gschanes A., Hutter-Paier B. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neurol Transm 1998;Suppl 53:289-298.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.